A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes

Abstract

Tandem Control-IQ and Minimed 780G represent the most Advanced Hybrid Closed Loop (AHCL) systems currently available in pediatric and adult subjects with Type 1 Diabetes (T1D). We retrospectively compared clinical and continuous glucose monitoring data from 51 patients who upgraded to Minimed 780G system and have completed 1-month observation period with data from 39 patients who upgraded to Tandem Control-IQ. Inverse probability weighting was used to minimize the basal characteristics imbalances. Both AHCL systems showed a significant improvement in glycemic parameters. Minimed 780G group achieved higher TIR increase (p= 0.004) and greater reduction of blood glucose average (p= 0.001). Tandem Control-IQ system significantly reduced the occurrence of TBR (p= 0.010) and the Coefficient of Variation of glucose levels (p= 0.005). The use of ACHL systems led to a significant improvement of glycemic control substantially reaching the International recommended glycemic targets. Minimed 780G appears to be more effective in managing hyperglycemia, while Tandem Control-IQ seems to be more effective in reducing time in hypoglycemia.

One-Year Real-World Study on Comparison among Different Continuous Subcutaneous Insulin Infusion Devices for the Management of Pediatric Patients with Type 1 Diabetes: The Supremacy of Hybrid Closed-Loop Systems

“…PLGS systems use algorithms that can predict the occurrence of hypoglycemia and pre-emptively suspend insulin delivery [ 10 ]. Finally, the most innovative HCL systems automatically adjust insulin doses on the basis of CGM data [ 13 , 14 , 15 ].…”

Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus

“…The indexes of times spent in range analyzed included those recommended by the International Consensus on Glucose Monitoring of 2017 (TIR 70e180 mg/dl, TAR>180 mg/dl, TAR>250 mg/dl, TBR<70 mg/dl, TBR<54 mg/dl) [21], and those recommended by the International Consensus on Glucose Monitoring of 2019 (TIR 70e180 mg/dl, TAR180-250 mg/dl, TAR>250 mg/dl, TBR <70-54 mg/dl, TBR<54 mg/dl) [22]. These set of data were needed, given the limited evidence in literature so far reported, to the analyses of times in range with a follow up of less than two months [12e14] or in pediatric population [23].…”

To sleep or not to sleep: An Italian Control-IQ-uestion

“…A recent study in children demonstrates an improvement of TIR with Control-IQ in comparison with Basal-IQ, a predictive low-glucose suspend (PLGS) algorithm ( 17 ). A single multicenter study that compared AHCL systems currently approved for the pediatric population showed the non-inferiority of the efficacy of Tandem Control-IQ in reaching glycemic targets compared with the other systems ( 18 ). Recent studies on the real-world use of the Tandem Control-IQ system confirmed the conclusions reached by the pivotal trials and previous studies.…”